Topical Prescription Management

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Atopic dermatitis (AD) management increasingly incorporates advanced topical therapies.
• Topical corticosteroids (TCSs) remain crucial, necessitating careful use to mitigate side effects.
• Steroid-sparing agents are vital for managing AD symptoms and improving patient outcomes.

Purpose of the Study:

• To review recent advances in topical therapies for atopic dermatitis.
• To highlight the role of steroid-sparing agents and novel treatments in AD management.
• To emphasize the importance of topical interventions in the comprehensive care of AD.

Main Methods:

• Literature review of recent advances in topical therapies for atopic dermatitis.
• Analysis of the efficacy and safety profiles of various topical agents.
• Discussion of emerging treatments, including tapinarof and live biotherapeutics.

Main Results:

• Steroid-sparing options such as calcineurin inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase-4 (PDE-4) inhibitors are effective for AD.
• These alternatives provide rapid itch relief and improve disease severity, complementing emollient use.
• Novel topical treatments, including tapinarof and microbiome-modulating biotherapeutics, show promise for AD management.

Conclusions:

• The landscape of topical AD treatment has expanded significantly with novel therapeutic options.
• Careful selection and use of topical treatments, including TCSs and steroid-sparing agents, are essential for effective AD management.
• Emerging topical therapies offer diverse and promising strategies for improving outcomes in patients with atopic dermatitis.